Featured Articles
Editas Medicine Inc. (NASDAQ:EDIT), and Allergan plc (NYSE:AGN), progress option rights to develop CRISPR technology for treatment of LCA 10
Editas Medicine, Inc. (NASDAQ: EDIT), based in Dublin, Ireland and Cambridge, Massachusetts, and Allergan plc (NYSE: AGN), also headquartered in Dublin, Ireland have announced the exercise of an Allergan option to develop and commercialize “EDIT-101” – a CRISPR-based technology for the treatment of Leber Congenital Amaurosis type 10 (LCA10). CRISPR (an acronym for “clustered regularly […]
Read full storyPhase II results for sustained release ranibizumab treatment of AMD indicate patients may only require two ophthalmic visits per year
Anti-VEGF treatment of exudative age-related macular degeneration has represented a paradigm shift in the medical management of the disease however, not all patients obtain the same benefit and the burden of potentially monthly injections and ophthalmic visits can often reduce the effectiveness of the treatment. In an effort to overcome some of these challenges, a […]
Read full storyFirst genome-wide association (GWAS) study on the systemic complement activation system identifies markers potentially significant for treatment of AMD
Researchers based at the Department of Ophthalmology at Radboud University Medical Center, Nijmegen, the Netherlands, have shown that variants of the CFH and CFHR4 genes are associated with variation in the systemic complement activation system, and thereby potentially relevant to how certain AMD patients may respond to therapeutics based on complement biology. The research, conducted […]
Read full story